VEGFA and atrophic macular degeneration: The antibody fragment inhibits binding of multiple active forms of VEGF-A to their receptors, resolves leakage, and restores retinal morphology and often function, and became the first-line treatment for neovascular AMD.9–14 Recently, an increased progression rate of geographic atrophy (GA) has been recognized during anti-VEGF therapy.15,16